Vermillion (NASDAQ: VRML) and Immunomedics (NASDAQ:IMMU) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Profitability

This table compares Vermillion and Immunomedics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vermillion -350.66% -283.32% -138.76%
Immunomedics -8,708.96% N/A -47.04%

Volatility and Risk

Vermillion has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Immunomedics has a beta of 1.72, suggesting that its share price is 72% more volatile than the S&P 500.

Valuation & Earnings

This table compares Vermillion and Immunomedics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vermillion $3.12 million 12.34 -$10.49 million N/A N/A
Immunomedics $3.09 million 1,278.68 -$153.20 million ($0.81) -29.15

Vermillion has higher revenue and earnings than Immunomedics.

Analyst Ratings

This is a summary of current recommendations and price targets for Vermillion and Immunomedics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vermillion 0 1 0 0 2.00
Immunomedics 0 0 3 0 3.00

Vermillion presently has a consensus target price of $2.25, suggesting a potential upside of 309.24%. Immunomedics has a consensus target price of $37.00, suggesting a potential upside of 56.71%. Given Vermillion’s higher probable upside, analysts clearly believe Vermillion is more favorable than Immunomedics.

Institutional & Insider Ownership

28.1% of Vermillion shares are held by institutional investors. Comparatively, 74.4% of Immunomedics shares are held by institutional investors. 4.3% of Vermillion shares are held by insiders. Comparatively, 14.8% of Immunomedics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Immunomedics beats Vermillion on 8 of the 12 factors compared between the two stocks.

Vermillion Company Profile

Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic (IVD) trial services to third-party customers; and laboratory services to meet the needs of IVD manufacturers to commercialize high-complexity assays. The company serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.

Immunomedics Company Profile

Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody; and a collaboration agreement with University of Wisconsin Carbone Cancer Center to expand IMMU-132 into prostate cancer. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.

Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.